**Name of Journal:** *World Journal of Meta-Analysis*

**Manuscript NO:** 63185

**Manuscript Type:** MINIREVIEWS

**Viral hepatitis: A brief introduction, review of management, advances and challenges**

Fagan O *et al*. Viral hepatitis

Olga Fagan, Paul Amstrong, Kevin Van Der Merwe, Daniela Crosnoi, Chris Steele, Julia Sopena-Falco, Vikrant Parihar

**Olga Fagan, Paul Amstrong, Kevin Van Der Merwe, Daniela Crosnoi, Chris Steele, Vikrant Parihar,** Department of Gastroenterology, Letterkenny University Hospital, Letterkenny F92 AE81, Ireland

**Julia Sopena-Falco,** Department of Gastroenterology, Saint Vincent’s University Hospital, Dublin 04, Ireland

**Author contributions:** The authors were involved in writing different aspects of the draft which were put together and amended by the last author.

**Corresponding author: Vikrant Parihar, MBBS, MD, MRCP, Consultant Physician-Scientist,** Department of Gastroenterology, Letterkenny University Hospital, Kilmacrennan Road, Letterkenny F92 AE81, Ireland. vikpar37@yahoo.com

**Received:** January 27, 2021

**Revised:** February 26, 2021

**Accepted:** April 23, 2021

**Published online:**

**Abstract**

Viral hepatitis represents a major public health hazard and is associated with significant global mortality. Over the last decade, there have been significant developments in the prevention and treatment of viral hepatitis. These changes have led to a situation whereby global elimination has become a realistic goal, fully endorsed by the World Health Organization (WHO). By 2030, the WHO aims to reduce viral hepatitis mortality by 65% and reduce new infections by 90% by 2030. These are ambitious targets and will only be met through a sustained programme. This will require expertise from hepatologists and virologists and the fields of public health and primary care. In this article, we review the causes of viral hepatitis, its management through prevention and treatments, and the most pressing challenges and recent advances.

**Key Words:** Viral Hepatitis; Management; Direct-acting antivirals; Advances; Challenges

Fagan O, Amstrong P, Merwe KVD, Crosnoi D, Steele C, Sopena-Falco J, Parihar V. Viral hepatitis: A brief introduction, review of management, advances and challenges. *World J Meta-Anal* 2021; In press

**Core Tip:** Viral hepatitis represents a major public health hazard and is associated with significant global mortality. The aim of this article is to provide a concise description of the management, advances and challenges in the field of hepatitis caused by hepatotropic viruses A-E.

**INTRODUCTION**

Viral hepatitis has a high prevalence and is a leading cause of death worldwide, accounting for 1.34 million deaths worldwide in 2015[1]. Lots of different viruses are known to cause liver inflammation, including hepatotropic viruses named A to E. Most of these result in acute self-limiting disease; however, hepatitis B (HBV), HCV, HDV and HEV can become chronic (Table 1). Other viruses (such as Cytomegalovirus and Epstein-Barr virus) can also cause hepatitis as part of a systemic infection. This review considers only hepatitis caused by hepatotropic viruses.

Hepatitis A and E are transmitted through the faecal-oral route by contact with contaminated food or water[2]*.* In contrast, hepatitis B, C and D are transmitted through bodily fluids[3].

Chronic hepatitis is defined as chronic inflammatory reaction in the liver, as reflected in liver function tests and histology for at least 6 mo[4]. Chronic hepatitis B/C/D/E is defined as the presence of virus (in blood, or in stool for HEV) for more than 6 mo after the new onset of infection. Acute liver failure (ALF) is a syndrome of severe hepatic dysfunction associated with encephalopathy and/or coagulopathy. The American Association for the Study of Liver Diseases (AASLD) define it as “evidence of coagulation abnormality, usually an international normalized ratio above 1.5, and any degree of mental alteration (encephalopathy) in a patient without pre-existing liver disease and with an illness of less than 26 wk’ duration”[5]. Globally viral hepatitis remains a large causal contributor to ALF[6] and accounts for the majority of ALF in Asia and Africa[7]. Viral induced ALF is associated with mortality of 18%-91% (with a combined mortality of 50%) in low income countries compared with 3%-45% (with combined mortality of 26%) in upper middle income countries[7].

**Epidemiology**

***HAV***

The World Health Organization (WHO) estimated in 2005, 126 million people were affected[8]. Unsurprisingly, the highest rates of HAV infection are found in areas with poor sanitary conditions[9].

***HBV***

Roughly 30% of the world’s population show evidence of current or past infection with HBV[10]. Globally, most HBV infections occur through vertical mother-to-child and early-life horizontal transmission[11]*.*

There are 5 phases of chronic HBV infection[12]. (1) Phase 1: High replicative state with hepatitis B e-antigen (HBeAg)-positive (previously known as ‘immune tolerant’). High HBV-DNA levels > 106 IU/mL, often normal or slightly increased alanine transaminase (ALT) levels; minimal or no inflammatory changes on liver biopsy; (2) Phase 2: HBeAg-positive chronic HBV. Variable HBV-DNA levels, higher ALT than the previous phase; moderate/severe inflammatory changes on liver biopsy. Can last for months to years; (3) Phase 3: HBeAg-negative chronic HBV (previously known as ‘inactive carrier’). Generally, low HBV-DNA levels, normal ALT; the severity of fibrosis depends on the previous stage, but active inflammation is low; (4) Phase 4: HBeAg-negative chronic hepatitis. Variability in HBV-DNA level, ALT and inflammatory changes on liver biopsy. The annual spontaneous clearance of chronic HBV is about 1%[13]; and (5) Phase 5: Occult infection [Hepatitis B surface antigen (HBsAg)-negative]. Undetectable/very low serum HBV DNA with hepatitis B core antibody (Anti-HBc), with or without hepatitis B surface antibody and normal ALT. HBsAg loss before the development of cirrhosis is associated with minimal risk of cirrhosis and improved survival. Immunosuppression may lead to HBV reactivation in these patients.

The HBV genome incorporates into the host genome and is postulated to have an oncogenesis effect contributing to hepatocellular carcinoma (HCC) development[14]. Assay of the novel (or “emerging”) biomarker hepatitis B core-related antigen (HBcrAg) is helpful in monitoring patients with chronic HBV infection. Serum HBV DNA correlates with HBcrAg. In patients with undetectable HBV DNA or loss of HBsAg, HBcrAg can still be detected[15]. Decreasing HBcrAg titres are associated with positive outcomes for chronic HBV infected patients[16].

***HCV***

It is estimated 1.75 million people were newly infected with HCV in 2015[17]. It is the most common bloodborne infection in the USA and the western world[18]. Ninety per cent of HCV infections will progress to chronic liver disease[19]. The most common risk factor for HCV contraction is intravenous drug use, accounting for 80% of cases, with receipt of blood products representing 10.8%[20]. Other less common routes of transmission include organ transplantation, haemodialysis and tattooing.

The WHO estimated that 71 million people were living with chronic HCV infection in 2015[21]. This, however, is not reflected in diagnoses: only 20% of those who were estimated to be infected were diagnosed in 2016[21], and only 13% of these were treated with direct-acting antivirals (DAAs).

Eighty per cent of HCV infections are found in 31 of 194 countries, with the highest incidences found in Eastern Mediterranean and Eastern European countries[22].

Due to this propensity of the virus to develop into fibrosis, cirrhosis, and HCC, the death rate from HCV is rising despite a reduced incidence. Chronic HCV is often complicated by extra-hepatic diseases such as cryoglobulinemia associated vasculitis, renal disease, and type 2 diabetes[23]. These factors reinforce the importance of treating HCV.

***HDV***

The incidence and prevalence of HDV is largely uncertain[21]. Some estimate 12 million cases globally; however, there is speculation this could be even higher with cases as high as 60 million[24].

***HEV***

Twenty million infections of HEV are estimated annually with about 3 million of these causing symptomatic disease[25]. This is predominantly found in south and east Asia, with genotypes 1-4 of 8 affecting humans[26]. This is predominantly transmitted through the faecal-oral route; however, other more recently discovered modes of transmission include blood transfusion, zoonotic infections (through consumption of infected meats) and organ transplants[27].

**Diagnosis**

The diagnoses of viral hepatitis are primarily made through both serological and molecular assays[28,29]. Serological tests can be either rapid diagnostic tests (field use) or laboratory-based enzyme immunoassays (Table 2).

There is a difficulty in diagnosing viral hepatitis as a cause of ALF. A study in Germany found nearly 50% of cases of HEV causing ALF were misdiagnosed as drug induced liver injuries[30]. Serological testing of HEV alone is often insufficient and molecular testing with polymerase chain reaction needs to be considered more[31].

**Prevention**

Interventions to mitigate contraction of viral hepatitis include sanitation, vaccination, harm reduction policies and safe blood supply practices.

***Sanitation***

Sanitation has improved worldwide, resulting in reduced annual numbers of diarrheal diseases and of HAV and HEV infections[32].

***Vaccination***

An effective HAV vaccine has existed since 1992. Adopting wide-scale HAV vaccination depends on socioeconomic conditions. Thirty-four countries have successfully introduced or are planning to introduce universal childhood HAV vaccination as of 2019[33].

The widespread introduction of a universal childhood HBV vaccine (3 doses) has reduced acute and chronic HBV infection worldwide. In 2013, 183 of 194 countries had introduced the HBV vaccine, and worldwide coverage with three HBV vaccine doses was estimated at 81%[34]. The use of antivirals in pregnant mothers with high HBV levels and immunoglobulins with HBV vaccination in infants born within 12hrs can prevent vertical transmission[35,36].

***Needle and syringe programmes***

Needle and syringe programmes are known to reduce the incidence of HIV without increasing the frequency of persons injecting drugs[37]. The data for reducing HCV incidence are equivocal; as HCV is more efficiently transmitted the aim would be for individuals to inject for the first time in the facility with clean needles and not contract HCV[38].

***The advent of standardised HEV testing in meat***

HEV infection has increased 10-fold over the past 10 years in Europe. Food-borne infections are linked predominantly with pig meat but also wild boar and deer meat. Currently the only prevention or control option is heat treatment and adequate cooking. Presently the awareness of HEV infection risk associated with undercooked pork is poor and could be optimised[39].

**Review of Management**

Management of acute viral hepatitis is mainly supportive except in the instance of ALF, which requires urgent referral to a liver transplant centre to evaluate liver transplantation.

***Treatment***

**HAV:** Supportive management is the mainstay of treatment for HAV, which commonly resolves spontaneously.

**HBV:** When considering management of HBV, one must remember that the virus itself is not cytopathic. Therefore, the clinical outcome following infection depends on the complex interplay between host immune response and viral replication. Acute HBV treatment is mainly supportive. The goal of therapy in chronic HBV is viral suppression to improve/stop liver inflammation and reduce the risk of cirrhosis, HCC and other complications[12,40].

Antiviral choices include tenofovir, entecavir, lamivudine, adefovir and telbivudine[41]. The treatment of chronic HBV depends on multiple factors, including the severity of inflammation/fibrosis, cirrhosis, ALT, E-Ag status, age and family history of HCC. The aim of chronic HBV therapy is the chronic sustained inhibition of viral replication, as curative rates are very low.

Table 3 sets out the recommended European Association for the Study of the Liver (EASL) guidelines for the treatment of those with chronic HBV.

Pegylated interferon-a (PEG-IFN-a) is a first line treatment option in chronic HBV infection. The advantage of PEG-IFN-a over nucelos(t)ide analogues is the finite treatment course, together with superior rates of HBsAg and HBeAg seroconversion[42]. However use of PEG-IFN-a is associated with greater adverse effects including psychiatric, neurologic and endocrinological, effects[43].

**HCV:** Acute HCV infection often results in mild acute illness lasting 2-12 wk, with less than 25% of infections identified clinically[44]. Eighty to ninety per cent go on to develop chronic HCV infection with 10%-20% of patients developing complications, including cirrhosis and HCC over decades[45]. DAAs are the mainstay of HCV treatment currently (Table 4). DAAs are highly effective at clearing the virus in > 90% of people. Sustained virologic response (SVR) is defined as aviremia 24 wk post completion of antiviral therapy for HCV infection[46]. However, there is some evidence to support the determination of SVR at 12 wk[47]. SVR at 24 wk remains the gold standard. EASL and the AASLD recommend that all HCV patients (both naïve and treatment-experienced) be offered therapy. Different genotypes respond better to different DAAs (Table 5). Pan-genotypic HCV drug regimens, including (sofosbuvir/velaptasvir) and (glecaprevir/pibrentasavir), can be used to treat patients without identifying their HCV genotype, simplifying therapy[48].

**HBV/HDV:** HDV is a major cause of severe acute and chronic hepatitis[49]. HDV requires the presence of HBV infection for its own viral cycle. HBV/HDV co-infection results in chronicity in 2% of cases; however, superinfection of HDV is associated with 90% chronicity. HDV is a highly pathogenic virus resulting in the most severe chronic hepatitis and the development of cirrhosis within 10 years of infection in 80% of cases[50]. Pegylated interferon can be used as a treatment, although significant data are lacking[51]*.* Currently HDV treatments are in phase II and III trials.

**HEV:** HEV infection is usually self-terminating in immunocompetent individuals, typically with detectable serum/stool HEV RNA present for approximately three weeks. In acute self-limiting disease, symptomatic management and management of cholestasis is the primary treatment.

Chronic hepatitis E infection is associated with genotypes 3, 4, 7[27,52]. In endemic areas, the faecal-oral route is the main mode of transmission, while in the developed world food-borne transmission is most common. Most chronic HEV infections are reported in developed countries and thus zoonotic transmission is assumed (through consumption of contaminated meat). Immunocompromised individuals are at an increased risk of contracting chronic HEV infection[53]. The high virulence of genotype 1 may increase the risk of chronic infection. Ribavirin is the agent of choice in chronic HEV infections[54]. Genotype 1 HEV infection can be severe in pregnancy. It has been associated with preterm labour and a maternal mortality rate of up to 30% in the third trimester[55].

The development of a HEV vaccine (Hecolin), licensed in China, has shown promise and efficacy in preventing HEV genotype 4 infection in healthy individuals 16–65 years[56].

**Advances**

***HAV***

The WHO’s 1992 recommendation of universal mass vaccination programmes in countries with a high risk HAV exposure has led to positive outcomes. The introduction of universal vaccination in countries with endemic HAV infections has resulted in decreased incidence of HAV as well as reduced cases amongst non-vaccinated individuals. Incidence reductions of 88% in Argentina, > 95% in Israel, 93% in Panama and 96% in Uruguay were observed over a 5-10 year period post introduction of a vaccination programme[57].

***HBV***

**WHO elimination strategy:** The WHO and its member states aim to eliminate viral hepatitis by 2030. This is a historic commitment which has allowed for funding and resource advocacy internationally. Undoubtedly the impact of the current global pandemic with COVID-19 coronavirus will adversely impact the provision of resources and funding.

**Updated HBV treatment guidelines on therapy discontinuation:** International guidelines have outlined endpoints for nucleos(t)ide analogues withdrawal, the optimum of which is loss of HBsAg. This is rarely achieved, however, due to the presence of covalently closed circular DNA (cccDNA). Surrogate markers of efficacy have been developed including viral suppression, transaminases normalisation and HBeAg seroconversion[12]. These markers are associated with cessation of inflammation and fibrosis advancement[58]. These surrogate markers are now considered as potential alternative endpoints: the seroconversion of HBeAg in non-cirrhotic patients with normal ALT levels and viral suppression can discontinue treatment post 1 year[12,59] (or 3 years as per APASL). Over the last year there is growing evidence of the potential benefit of stopping nucelos(t)ide analogue treatment in selected groups, including a greater reduction in quantitative HBsAg seroconversion in those who discontinue nucelos(t)ide analogue treatment[60,61].

***HCV***

**Advent of DAAs allowing successful HCV eradication:** The advent of DAAs with complete eradication of the HCV is one of the most critical advances in hepatology. Their increased efficacy, safety and tolerability make DAAs a welcome alternative to interferon-based therapy. These treatments now boast SVR rates > 90%.

Interferon-alpha (IFN-a) monotherapy was the mainstay of treatment until the 1990s. The advent of IFN-a and ribavirin combination therapy saw SVR of 38% with a 48-wk course[62]. This was further boosted to an SVR rate of 55% using pegylated-IFN[63]. Increased understanding of the HCV’s molecular virology and life cycle enabled the synthesis of the first DAAs, namely the Ns3/4A protease inhibitors telaprevir and boceprevir. These, when used in combination with Peg-IFN and ribavirin, achieved an SVR rate of 65%-75%[64]. Use of this 'triple therapy' gained FDA approval in 2011. Later, sofosbuvir's development achieved 82 and 95% SVR rates when used with ribavirin alone[65]. The use of a DAA therapy alone (sofosbuvir and ledipasvir) demonstrated SVR rates of 94%-99% at 12 wk in three pivotal trials comparing DAA combinations (with and without ribavirin) in both treatment-naïve and treatment-experienced patients[66-68]. There are currently 10 FDA-approved DAAs.

***HDV***

**Development of new treatments:** Newly developed treatments for HDV are promising. These include viral assembly point inhibitors, virus entry point inhibitors (Bulvertide phase II and III trials NCT03852719, approved by EU in July 2020)[69] and prenylation inhibitors (lonafarnib in combination with ritonavir and Peg-IFN, phase III trials NCT03719313)[70].

***HEV***

**Improved understanding of its pathogenesis and extra-hepatic manifestations:** Improved understanding and awareness of extra-hepatic manifestations has improved HEV diagnosis and thus treatment. These include conditions such as Guillain-Barré[71,72], cryoglobulinemia’s[73], cardiac arrythmias[74] and pancreatitis[75] to name a few.

Development of HEV vaccine in China has proved effect further study is needed to demonstrates it long-term effect[56].

**Challenges**

***HBV***

**Prevention of vertical transmission in African countries:** The first HBV vaccine dose should be administered within 24 h of birth (“the birth dose”). This has proven challenging, particularly in countries where home births predominate. Only 94 of 194 countries have established scheduled birth dose HBV vaccination, with an estimated 38% of children worldwide receiving this crucial dose[1]. This needs to be addressed in an attempt to reduce vertical transmission.

**Difficulty with early diagnosis:** As previously mentioned in this article, HBV is underdiagnosed and indeed people are often diagnosed late in life. In Asia, HBV is the main cause of HCC and the main cause of liver transplantation[76]. Failure to access diagnostics and a lack of screening programmes perpetuate this situation[28].

**Reactivation in the context of Immunosuppression:** HBV reactivation is the reappearance or rise of HBV DNA in those with past or chronic HBV infection. Reactivation may occur in a range of clinical scenarios predominantly in the context of an immunosuppressed state of immunosuppressive therapy. Reactivation of HBV is frequently reported in patients undergoing chemotherapy for haematological malignancies and post hematopoietic stem cell transplants[77].

**Chronic HBV relapse:** In contrast to HCV, the current antiviral therapy does not have the potential of HBV eradication. cccDNA is a replication template of HBV: The pre-genomic portion can be reverse transcribed into DNA. This cccDNA is not targeted by antiviral nucleot(s)ide analogues and can act as a viral relapse reservoir. The uncertainty of therapy course length is associated with patient compliance, resistance, safety and financial cost. To combat therapy length uncertainty (see Advances section), EASL proposed three endpoints for antiviral treatment of chronic HBV in 2009. These are: (1) HBsAg clearance; (2) HBeAg seroconversion; and (3) persistent inhibition of HBV DNA replication[12]. However, withdrawal of treatment is still associated with significant relapse rate and the 2015 Chinese guidelines for chronic HBV infection suggest extending therapy for three years post-HBeAg seroconversion[40]. Neither the AASLD nor the EASL advises extending therapy post-HBeAg seroconversion[12,59]. Long-term nucleot(s)ide analogue use can produce resistance and side-effects. A resistance rate of 70% has been reported in patients using lamivudine for 5-years[12]. Long term use of adefovir and tenofovir can result in renal impairment[78].

***HCV***

**Stigma and inequity:** Harm reduction strategies have been proven to work; however, the failure of implementation may be secondary to the stigma associated with persons injecting drugs. As this group tends not to vote, their concerns are not advocated. Policy makers often overlook such interventions, being swayed instead by voters’ issues. Because HCV is relatively asymptomatic, a large proportion of the population are unaware of their diagnosis.

**Access to DAA therapy:** Global access to HBV and HCV therapy remains a problem. This is a multifactorial issue that includes access to diagnostics, therapy affordability and public health issues. Only approximately 1.7-million of the estimated 250 million individuals worldwide with chronic HBV were on treatment in 2015/2016[21]. Of the estimated 71 million people living with HCV, about 20% were aware of their diagnosis and about 5 million were treated with DAAs by the end of 2017[18]. Improved access to affordable non-hospital diagnostics is needed, as well as access to treatment. Attempts to combat these shortcomings include the addition of viral hepatitis diagnostics to the WHO’s proposed Essential Diagnostics List in 2016[79]. Development of point of care molecular testing is promising, but this needs to be affordable if it is to be used in low to middle-income countries[80]. Intellectual property or patenting remains a barrier to access to generic therapy and thus, to affordable treatment. Voluntary licencing agreements and those created through the Medicines Patent Pool (MPP) allow the manufacture and sale of generic DAAs, improving affordability. The proposed licensing of pibrentasvir and glecaprevir with the MPP would facilitate access to generic alternatives of important pan-genotypic therapy for HCV in low to middle-income countries[81]. Licensing of tenofovir and its generics with the MPP has allowed improved access in low to middle-income countries[82]. Further work and support of HCV eradication, and of HBV viral suppression programmes, are needed at both national and global level.

**DAA resistance:** The emergence of resistance to DAAs is a crucial challenge. The HCV high replication rate (estimated at 1012 copies per day) and the viral protein responsible for replications (RNA-dependent RNA polymerase, RdRp) demonstrates an absence of proofreading; therefore, HCV replication has a high error rate[83]. This results in multiple mutated viruses known as quasi-species, circulating in the blood[84]. Although the mutated viruses/quasi-species have less fitness (*i.e.*, ability to replicate) when an individual is treated with DAAs, one sees the quantity of the wildtype virus fall and the mutated virus rise. These mutated viruses/quasi-species can lead to structural changes in the protein/enzyme that the DAAs act on, thus generating resistance[85]. Resistance-associated-substitutions or RASs confer this resistance. The viral population that carry RASs are known as resistant variant (RAV). This can lead to RAV outgrowing the DAA-sensitive viruses during treatment (known as ‘breakthrough’) or after treatment (known as ‘relapse’). Therefore, the emergence of resistance is also determined by the level of previous therapeutic drug exposure.

**HDV:** Arguably HDV represents the largest challenge in treatment as it confers the most severe acute and chronic hepatitis and thus worst outcomes.

**CONCLUSION**

In conclusion, viral hepatitis is due to a group of pathogens that are associated with significant disease complications and morbidity. The increased awareness of viral hepatitis disease burden and the arrival of effective treatments for HBV and HCV have enhanced efforts and calls for action to eradicate viral hepatitis, as outlined by the United Nations WHO 2030 agenda[17,86,87].

**REFERENCES**

1 **World Health Organization**. Viral hepatitis: a hidden killer gains visibility, 2017. [cited 10 January 2021]. Available from: https://www.who.int/publications/10-year-review/hepatitis/en/

2 **Sinn DH**, Cho EJ, Kim JH, Kim DY, Kim YJ, Choi MS. Current status and strategies for viral hepatitis control in Korea. *Clin Mol Hepatol* 2017; **23**: 189-195 [PMID: 28942620 DOI: 10.3350/cmh.2017.0033]

3 **Tu T**, Patel K, Shackel NA. Chapter 17 - Viral Hepatitis. In: David SP, editor. Genomic and Precision Medicine (Third Edition). Boston: Academic Press, 2017: 317-340

4 **Sherlock S**. Chronic hepatitis. *Gut* 1974; **15**: 581-597 [PMID: 4609843 DOI: 10.1136/gut.15.7.581]

5 **Lee WM LA,** Stravitz RT. The management of acute liver failure: Update 2011. [cited 10 January 2021]. Available from: https://www.aasld.org/sites/default/files/2019-06/AcuteLiverFailureUpdate201journalformat1.pdf.

6 **Bernal W**, Wendon J. Acute liver failure. *N Engl J Med* 2013; **369**: 2525-2534 [PMID: 24369077 DOI: 10.1056/NEJMra1208937]

7 **Morabito V**, Adebayo D. Fulminant Hepatitis: Definitions, Causes and Management. *Health* 2014; **6**: 1038-1048

8 WHO position paper on hepatitis A vaccines – June 2012. *Wkly Epidemiol Rec* 2012; **87**: 261–76 [PMID: 22905367]

9 **Jacobsen KH**, Koopman JS. The effects of socioeconomic development on worldwide hepatitis A virus seroprevalence patterns. *Int J Epidemiol* 2005; **34**: 600-609 [PMID: 15831565 DOI: 10.1093/ije/dyi062]

10 **Trépo C**, Chan HL, Lok A. Hepatitis B virus infection. *Lancet* 2014; **384**: 2053-2063 [PMID: 24954675 DOI: 10.1016/S0140-6736(14)60220-8]

11 **Goldstein ST**, Zhou F, Hadler SC, Bell BP, Mast EE, Margolis HS. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. *Int J Epidemiol* 2005; **34**: 1329-1339 [PMID: 16249217 DOI: 10.1093/ije/dyi206]

12 **European Association for the Study of the Liver**.EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. *J Hepatol* 2017; **67**: 370-398 [PMID: 28427875 DOI: 10.1016/j.jhep.2017.03.021]

13 **Zhou K**, Contag C, Whitaker E, Terrault N. Spontaneous loss of surface antigen among adults living with chronic hepatitis B virus infection: a systematic review and pooled meta-analyses. *Lancet Gastroenterol Hepatol* 2019; **4**: 227-238 [PMID: 30679109 DOI: 10.1016/S2468-1253(18)30308-X]

14 **Xu HZ**, Liu YP, Guleng B, Ren JL. Hepatitis B Virus-Related Hepatocellular Carcinoma: Pathogenic Mechanisms and Novel Therapeutic Interventions. *Gastrointest Tumors* 2014; **1**: 135-145 [PMID: 26676160 DOI: 10.1159/000365307]

15 **Wong DK**, Seto WK, Cheung KS, Chong CK, Huang FY, Fung J, Lai CL, Yuen MF. Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA. *Liver Int* 2017; **37**: 995-1001 [PMID: 27992681 DOI: 10.1111/liv.13346]

16 **Mak LY**, Wong DK, Cheung KS, Seto WK, Lai CL, Yuen MF. Review article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection. *Aliment Pharmacol Ther* 2018; **47**: 43-54 [PMID: 29035003 DOI: 10.1111/apt.14376]

17 **World Health Organization**. Global health sector strategy on viral hepatitis 2016-2021. [cited 10 January 2021]. Available from: https://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/

18 **World Health Organization**. Hepatitis C. [cited 10 January 2021]. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-c

19 **Alter MJ**, Margolis HS, Krawczynski K, Judson FN, Mares A, Alexander WJ, Hu PY, Miller JK, Gerber MA, Sampliner RE. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. *N Engl J Med* 1992; **327**: 1899-1905 [PMID: 1280771 DOI: 10.1056/NEJM199212313272702]

20 **Booth JC**, O'Grady J, Neuberger J; Thr Royal College of Physicians of London and the British Society of Gastroenterology. Clinical guidelines on the management of hepatitis C. *Gut* 2001; **49 Suppl 1**: I1-21 [PMID: 11413125 DOI: 10.1136/gut.49.suppl\_1.i1]

21 **World Health Organization**. Global hepatitis report 2017. [cited 10 January 2021]. Available from: https://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/

22 **Polaris Observatory HCV Collaborators**. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. *Lancet Gastroenterol Hepatol* 2017; **2**: 161-176 [PMID: 28404132 DOI: 10.1016/S2468-1253(16)30181-9]

23 **Cacoub P**, Comarmond C, Domont F, Savey L, Desbois AC, Saadoun D. Extrahepatic manifestations of chronic hepatitis C virus infection. *Ther Adv Infect Dis* 2016; **3**: 3-14 [PMID: 26862398 DOI: 10.1177/2049936115585942]

24 **Chen HY**, Shen DT, Ji DZ, Han PC, Zhang WM, Ma JF, Chen WS, Goyal H, Pan S, Xu HG. Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis. *Gut* 2019; **68**: 512-521 [PMID: 30228220 DOI: 10.1136/gutjnl-2018-316601]

25 **Hakim MS**, Wang W, Bramer WM, Geng J, Huang F, de Man RA, Peppelenbosch MP, Pan Q. The global burden of hepatitis E outbreaks: a systematic review. *Liver Int* 2017; **37**: 19-31 [PMID: 27542764 DOI: 10.1111/liv.13237]

26 **World Health Organization**. Hepatitis E, 2020. [cited 10 January 2021]. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-e

27 **Thakur V**, Ratho RK, Kumar S, Saxena SK, Bora I, Thakur P. Viral Hepatitis E and Chronicity: A Growing Public Health Concern. *Front Microbiol* 2020; **11**: 577339 [PMID: 33133046 DOI: 10.3389/fmicb.2020.577339]

28 **Allain JP**, Opare-Sem O. Screening and diagnosis of HBV in low-income and middle-income countries. *Nat Rev Gastroenterol Hepatol* 2016; **13**: 643-653 [PMID: 27625189 DOI: 10.1038/nrgastro.2016.138]

29 **Parry JV**, Easterbrook P, Sands AR. One or two serological assay testing strategy for diagnosis of HBV and HCV infection? The use of predictive modelling. *BMC Infect Dis* 2017; **17**: 705 [PMID: 29143611 DOI: 10.1186/s12879-017-2774-1]

30 **Manka P**, Bechmann LP, Coombes JD, Thodou V, Schlattjan M, Kahraman A, Syn WK, Saner F, Gerken G, Baba H, Verheyen J, Timm J, Canbay A. Hepatitis E Virus Infection as a Possible Cause of Acute Liver Failure in Europe. *Clin Gastroenterol Hepatol* 2015; **13**: 1836-1842.e2; quiz e157-8 [PMID: 25912835 DOI: 10.1016/j.cgh.2015.04.014]

31 **Anastasiou OE**, Thodou V, Berger A, Wedemeyer H, Ciesek S. Comprehensive Evaluation of Hepatitis E Serology and Molecular Testing in a Large Cohort. *Pathogens* 2020; **9** [PMID: 32093070 DOI: 10.3390/pathogens9020137]

32 **World Health Organization.** Preventing diarrhoea through better water, sanitation and hygiene: exposures and impacts in low- and middle-income countries, 2014. [cited 10 January 2021]. Available from: https://www.who.int/water\_sanitation\_health/diseases-risks/gbd\_poor\_water/en/

33 **World Health Organization**. Hepatitis A 2020. [cited 10 January 2021]. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-a

34 **World Health Organization**. WHO-UNICEF estimates of HepB3 coverage 2015. [cited 10 January 2021]. Available from: https://apps.who.int/immunization\_monitoring/globalsummary/timeseries/tswucoveragehepb3.html

35 **Kubo A**, Shlager L, Marks AR, Lakritz D, Beaumont C, Gabellini K, Corley DA. Prevention of vertical transmission of hepatitis B: an observational study. *Ann Intern Med* 2014; **160**: 828-835 [PMID: 24862434 DOI: 10.7326/M13-2529]

36 **Pan CQ**, Duan Z, Dai E, Zhang S, Han G, Wang Y, Zhang H, Zou H, Zhu B, Zhao W, Jiang H; China Study Group for the Mother-to-Child Transmission of Hepatitis B. Tenofovir to Prevent Hepatitis B Transmission in Mothers with High Viral Load. *N Engl J Med* 2016; **374**: 2324-2334 [PMID: 27305192 DOI: 10.1056/NEJMoa1508660]

37 **World Health Organization**. Effectiveness of sterile needle and syringe programming in reducing HIV/AIDS among injecting drug users. Geneva: World Health Organization, 2004

38 **MacArthur GJ**, van Velzen E, Palmateer N, Kimber J, Pharris A, Hope V, Taylor A, Roy K, Aspinall E, Goldberg D, Rhodes T, Hedrich D, Salminen M, Hickman M, Hutchinson SJ. Interventions to prevent HIV and Hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness. *Int J Drug Policy* 2014; **25**: 34-52 [PMID: 23973009 DOI: 10.1016/j.drugpo.2013.07.001]

39 **EFSA Panel on Biological Hazards (BIOHAZ).**, Ricci A, Allende A, Bolton D, Chemaly M, Davies R, Fernandez Escamez PS, Herman L, Koutsoumanis K, Lindqvist R, Nørrung B, Robertson L, Ru G, Sanaa M, Simmons M, Skandamis P, Snary E, Speybroeck N, Ter Kuile B, Threlfall J, Wahlström H, Di Bartolo I, Johne R, Pavio N, Rutjes S, van der Poel W, Vasickova P, Hempen M, Messens W, Rizzi V, Latronico F, Girones R. Public health risks associated with hepatitis E virus (HEV) as a food-borne pathogen. *EFSA J* 2017; **15**: e04886 [PMID: 32625551 DOI: 10.2903/j.efsa.2017.4886]

40 **Hou J**, Wang G, Wang F, Cheng J, Ren H, Zhuang H, Sun J, Li L, Li J, Meng Q, Zhao J, Duan Z, Jia J, Tang H, Sheng J, Peng J, Lu F, Xie Q, Wei L; Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Guideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update). *J Clin Transl Hepatol* 2017; **5**: 297-318 [PMID: 29226097 DOI: 10.14218/JCTH.2016.00019]

41 **Wong WWL**, Pechivanoglou P, Wong J, Bielecki JM, Haines A, Erman A, Saeed Y, Phoon A, Tadrous M, Younis M, Rayad NZ, Rac V, Janssen HLA, Krahn MD. Antiviral treatment for treatment-naïve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials. *Syst Rev* 2019; **8**: 207 [PMID: 31426837 DOI: 10.1186/s13643-019-1126-1]

42 **Rijckborst V**, Sonneveld MJ, Janssen HL. Review article: chronic hepatitis B - anti-viral or immunomodulatory therapy? *Aliment Pharmacol Ther* 2011; **33**: 501-513 [PMID: 21198707 DOI: 10.1111/j.1365-2036.2010.04555.x]

43 **Davoodi L**, Masoum B, Moosazadeh M, Jafarpour H, Haghshenas MR, Mousavi T. Psychiatric side effects of pegylated interferon-α and ribavirin therapy in Iranian patients with chronic hepatitis C: A meta-analysis. *Exp Ther Med* 2018; **16**: 971-978 [PMID: 30116347 DOI: 10.3892/etm.2018.6255]

44 **Spearman CW**, Dusheiko GM, Hellard M, Sonderup M. Hepatitis C. *Lancet* 2019; **394**: 1451-1466 [PMID: 31631857 DOI: 10.1016/S0140-6736(19)32320-7]

45 **Thein HH**, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. *Hepatology* 2008; **48**: 418-431 [PMID: 18563841 DOI: 10.1002/hep.22375]

46 **Ghany MG**, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. *Hepatology* 2009; **49**: 1335-1374 [PMID: 19330875 DOI: 10.1002/hep.22759]

47 **Martinot-Peignoux M**, Stern C, Maylin S, Ripault MP, Boyer N, Leclere L, Castelnau C, Giuily N, El Ray A, Cardoso AC, Moucari R, Asselah T, Marcellin P. Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. *Hepatology* 2010; **51**: 1122-1126 [PMID: 20069649 DOI: 10.1002/hep.23444]

48 **Li DK**, Chung RT. Overview of Direct-Acting Antiviral Drugs and Drug Resistance of Hepatitis C Virus. *Methods Mol Biol* 2019; **1911**: 3-32 [PMID: 30593615 DOI: 10.1007/978-1-4939-8976-8\_1]

49 **Rizzetto M**. The delta agent. *Hepatology* 1983; **3**: 729-737 [PMID: 6413350 DOI: 10.1002/hep.1840030518]

50 **Rizzetto M**, Verme G, Recchia S, Bonino F, Farci P, Aricò S, Calzia R, Picciotto A, Colombo M, Popper H. Chronic hepatitis in carriers of hepatitis B surface antigen, with intrahepatic expression of the delta antigen. An active and progressive disease unresponsive to immunosuppressive treatment. *Ann Intern Med* 1983; **98**: 437-441 [PMID: 6340574 DOI: 10.7326/0003-4819-98-4-437]

51 **Zarrin A**, Akhondi H. Viral Hepatitis. Treasure Island: Stat Pearls Publishing, 2020

52 **Geng Y**, Zhang H, Huang W, J Harrison T, Geng K, Li Z, Wang Y. Persistent hepatitis e virus genotype 4 infection in a child with acute lymphoblastic leukemia. *Hepat Mon* 2014; **14**: e15618 [PMID: 24596581 DOI: 10.5812/hepatmon.15618]

53 **Kamar N**, Dalton HR, Abravanel F, Izopet J. Hepatitis E virus infection. *Clin Microbiol Rev* 2014; **27**: 116-138 [PMID: 24396139 DOI: 10.1128/CMR.00057-13]

54 **Hui W**, Wei L, Li Z, Guo X. Treatment of Hepatitis E. *Adv Exp Med Biol* 2016; **948**: 211-221 [PMID: 27738987 DOI: 10.1007/978-94-024-0942-0\_12]

55 **Wu C**, Wu X, Xia J. Hepatitis E virus infection during pregnancy. *Virol J* 2020; **17**: 73 [PMID: 32522266 DOI: 10.1186/s12985-020-01343-9]

56 **Li SW**, Zhao Q, Wu T, Chen S, Zhang J, Xia NS. The development of a recombinant hepatitis E vaccine HEV 239. *Hum Vaccin Immunother* 2015; **11**: 908-914 [PMID: 25714510 DOI: 10.1080/21645515.2015.1008870]

57 **Stuurman AL**, Marano C, Bunge EM, De Moerlooze L, Shouval D. Impact of universal mass vaccination with monovalent inactivated hepatitis A vaccines - A systematic review. *Hum Vaccin Immunother* 2017; **13**: 724-736 [PMID: 27786671 DOI: 10.1080/21645515.2016.1242539]

58 **Marcellin P**, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, Washington MK, Germanidis G, Flaherty JF, Aguilar Schall R, Bornstein JD, Kitrinos KM, Subramanian GM, McHutchison JG, Heathcote EJ. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. *Lancet* 2013; **381**: 468-475 [PMID: 23234725 DOI: 10.1016/S0140-6736(12)61425-1]

59 **Terrault NA**, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH; American Association for the Study of Liver Diseases. AASLD guidelines for treatment of chronic hepatitis B. *Hepatology* 2016; **63**: 261-283 [PMID: 26566064 DOI: 10.1002/hep.28156]

60 **Berg T**, Simon KG, Mauss S, Schott E, Heyne R, Klass DM, Eisenbach C, Welzel TM, Zachoval R, Felten G, Schulze-Zur-Wiesch J, Cornberg M, Op den Brouw ML, Jump B, Reiser H, Gallo L, Warger T, Petersen J; FINITE CHB study investigators [First investigation in stopping TDF treatment after long-term virological suppression in HBeAg-negative chronic hepatitis B]. Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study. *J Hepatol* 2017; **67**: 918-924 [PMID: 28736139 DOI: 10.1016/j.jhep.2017.07.012]

61 **Tout I**, Loureiro D, Mansouri A, Soumelis V, Boyer N, Asselah T. Hepatitis B surface antigen seroclearance: Immune mechanisms, clinical impact, importance for drug development. *J Hepatol* 2020; **73**: 409-422 [PMID: 32333923 DOI: 10.1016/j.jhep.2020.04.013]

62 **McHutchison JG**, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. *N Engl J Med* 1998; **339**: 1485-1492 [PMID: 9819446 DOI: 10.1056/NEJM199811193392101]

63 **Manns MP**, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. *Lancet* 2001; **358**: 958-965 [PMID: 11583749 DOI: 10.1016/s0140-6736(01)06102-5]

64 **Wakita T**, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Kräusslich HG, Mizokami M, Bartenschlager R, Liang TJ. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. *Nat Med* 2005; **11**: 791-796 [PMID: 15951748 DOI: 10.1038/nm1268]

65 **Waheed Y**. Ledipasvir and sofosbuvir: Interferon free therapy for hepatitis C virus genotype 1 infection. *World J Virol* 2015; **4**: 33-35 [PMID: 25674516 DOI: 10.5501/wjv.v4.i1.33]

66 **Afdhal N**, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, Nahass R, Ghalib R, Gitlin N, Herring R, Lalezari J, Younes ZH, Pockros PJ, Di Bisceglie AM, Arora S, Subramanian GM, Zhu Y, Dvory-Sobol H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Sulkowski M, Kwo P; ION-2 Investigators. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. *N Engl J Med* 2014; **370**: 1483-1493 [PMID: 24725238 DOI: 10.1056/NEJMoa1316366]

67 **Afdhal N**, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gomez M, Zarski JP, Agarwal K, Buggisch P, Foster GR, Bräu N, Buti M, Jacobson IM, Subramanian GM, Ding X, Mo H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Mangia A, Marcellin P; ION-1 Investigators. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. *N Engl J Med* 2014; **370**: 1889-1898 [PMID: 24725239 DOI: 10.1056/NEJMoa1402454]

68 **Kowdley KV**, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, Shiffman ML, Schiff E, Ghalib R, Ryan M, Rustgi V, Chojkier M, Herring R, Di Bisceglie AM, Pockros PJ, Subramanian GM, An D, Svarovskaia E, Hyland RH, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Pound D, Fried MW; ION-3 Investigators. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. *N Engl J Med* 2014; **370**: 1879-1888 [PMID: 24720702 DOI: 10.1056/NEJMoa1402355]

69 **European Medicines Agency**. bulevirtide 2020. [cited 10 January 2021]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/hepcludex

70 **Asselah T**, Loureiro D, Tout I, Castelnau C, Boyer N, Marcellin P, Mansouri A. Future treatments for hepatitis delta virus infection. *Liver Int* 2020; **40 Suppl 1**: 54-60 [PMID: 32077603 DOI: 10.1111/liv.14356]

71 **Perrin HB**, Cintas P, Abravanel F, Gérolami R, d'Alteroche L, Raynal JN, Alric L, Dupuis E, Prudhomme L, Vaucher E, Couzigou P, Liversain JM, Bureau C, Vinel JP, Kamar N, Izopet J, Peron JM. Neurologic Disorders in Immunocompetent Patients with Autochthonous Acute Hepatitis E. *Emerg Infect Dis* 2015; **21**: 1928-1934 [PMID: 26490255 DOI: 10.3201/eid2111.141789]

72 **Choudhary MC**, Bajpai V, Anand L, Gupta E. Guillain-Barré syndrome in a patient of acute Hepatitis E virus infection associated with genotype 1: Case report and literature review. *Intractable Rare Dis Res* 2019; **8**: 43-47 [PMID: 30881857 DOI: 10.5582/irdr.2018.01099]

73 **Marion O**, Abravanel F, Del Bello A, Esposito L, Lhomme S, Puissant-Lubrano B, Alric L, Faguer S, Izopet J, Kamar N. Hepatitis E virus-associated cryoglobulinemia in solid-organ-transplant recipients. *Liver Int* 2018; **38**: 2178-2189 [PMID: 29845733 DOI: 10.1111/liv.13894]

74 **Woolson KL**, Forbes A, Vine L, Beynon L, McElhinney L, Panayi V, Hunter JG, Madden RG, Glasgow T, Kotecha A, Dalton HC, Mihailescu L, Warshow U, Hussaini HS, Palmer J, Mclean BN, Haywood B, Bendall RP, Dalton HR. Extra-hepatic manifestations of autochthonous hepatitis E infection. *Aliment Pharmacol Ther* 2014; **40**: 1282-1291 [PMID: 25303615 DOI: 10.1111/apt.12986]

75 **Somani SK**, Ghosh A, Awasthi G. Severe acute pancreatitis with pseudocyst bleeding due to hepatitis E virus infection. *Clin J Gastroenterol* 2009; **2**: 39-42 [PMID: 26191807 DOI: 10.1007/s12328-008-0035-y]

76 **Bosch FX**, Ribes J, Cléries R, Díaz M. Epidemiology of hepatocellular carcinoma. *Clin Liver Dis* 2005; **9**: 191-211, v [PMID: 15831268 DOI: 10.1016/j.cld.2004.12.009]

77 **Keam B**, Lee JH, Im SA, Yoon JH. Why, when, and how to prevent hepatitis B virus reactivation in cancer patients undergoing chemotherapy. *J Natl Compr Canc Netw* 2011; **9**: 465-477 [PMID: 21550967 DOI: 10.6004/jnccn.2011.0045]

78 **Gara N**, Zhao X, Collins MT, Chong WH, Kleiner DE, Jake Liang T, Ghany MG, Hoofnagle JH. Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B. *Aliment Pharmacol Ther* 2012; **35**: 1317-1325 [PMID: 22506503 DOI: 10.1111/j.1365-2036.2012.05093.x]

79 **World Health Organization**. Essential medicines and health products (2019). [cited 10 January 2021]. Available from: https://www.who.int/medicines/news/2019/updates-global-guidance-on-medicines-and-diagnostic-tests/en/

80 **Médecins Sans Frontières**. Putting HIV and HCV to the Test 2017. [cited 10 January 2021]. Available from: https://msfaccess.org/putting-hiv-and-hcv-test-3rd-ed-2017

81 **Abbvie**. AbbVie and the Medicines Patent Pool Complete New Licensing Agreement to Ensure Sustainable Access to Pan-genotypic Hepatitis C Medicine Glecaprevir/Pibrentasvir 2018. [cited 10 January 2021]. Available from: https://news.abbvie.com/news/media-statements/abbvie-and-medicines-patent-pool-complete-new-licensing-agreement-to-ensure-sustainable-access-to-pan-genotypic-hepatitis-c-medicine-glecaprevirpibrentasvir.htm

82 **Medicines Patent Pool**. The Medicines Patent Pool (MPP) Broadens Collaboration with Gilead Sciences: Signs Licence for Phase III Medicine Tenofovir Alafenamide (TAF). [cited 10 January 2021]. Available from: https://www.prnewswire.com/news-releases/the-medicines-patent-pool-mpp-broadens-collaboration-with-gilead-sciences-signs-licence-for-phase-iii-medicine-tenofovir-alafenamide-taf-268388772.html

83 **Benhamou Y**, Moussalli J, Ratziu V, Lebray P, Gysen V, de Backer K, Vangeneugden T, Picchio G, Beumont-Mauviel M. Results of A Proof of Concept Study (C210) of Telaprevir Monotherapy and in Combination with Peginterferon Alfa-2a And Ribavirin in Treatment-Naive Genotype 4 HCV Patients. *J Hepatol* 2009; **50**: S6 [DOI: 10.1016/S0168-8278(09)60012-X]

84 **Laskus T**, Wilkinson J, Gallegos-Orozco JF, Radkowski M, Adair DM, Nowicki M, Operskalski E, Buskell Z, Seeff LB, Vargas H, Rakela J. Analysis of hepatitis C virus quasispecies transmission and evolution in patients infected through blood transfusion. *Gastroenterology* 2004; **127**: 764-776 [PMID: 15362033 DOI: 10.1053/j.gastro.2004.06.005]

85 **Sentandreu V**, Jiménez-Hernández N, Torres-Puente M, Bracho MA, Valero A, Gosalbes MJ, Ortega E, Moya A, González-Candelas F. Evidence of recombination in intrapatient populations of hepatitis C virus. *PLoS One* 2008; **3**: e3239 [PMID: 18800167 DOI: 10.1371/journal.pone.0003239]

86 **Lee BX**, Kjaerulf F, Turner S, Cohen L, Donnelly PD, Muggah R, Davis R, Realini A, Kieselbach B, MacGregor LS, Waller I, Gordon R, Moloney-Kitts M, Lee G, Gilligan J. Transforming Our World: Implementing the 2030 Agenda Through Sustainable Development Goal Indicators. *J Public Health Policy* 2016; **37 Suppl 1**: 13-31 [PMID: 27638240 DOI: 10.1057/s41271-016-0002-7]

87 **European Union HCV Collaborators**. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. *Lancet Gastroenterol Hepatol* 2017; **2**: 325-336 [PMID: 28397696 DOI: 10.1016/S2468-1253(17)30045-6]

88 **Schweitzer A**, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. *Lancet* 2015; **386**: 1546-1555 [PMID: 26231459 DOI: 10.1016/S0140-6736(15)61412-X]

89 **Wedemeyer H**, Negro F. Devil hepatitis D: an orphan disease or largely underdiagnosed? *Gut* 2019; **68**: 381-382 [PMID: 30368454 DOI: 10.1136/gutjnl-2018-317403]

90 **Stockdale AJ**, Kreuels B, Henrion MYR, Giorgi E, Kyomuhangi I, de Martel C, Hutin Y, Geretti AM. The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis. *J Hepatol* 2020; **73**: 523-532 [PMID: 32335166 DOI: 10.1016/j.jhep.2020.04.008]

91 **Kamar N**, Izopet J, Dalton HR. Chronic hepatitis e virus infection and treatment. *J Clin Exp Hepatol* 2013; **3**: 134-140 [PMID: 25755487 DOI: 10.1016/j.jceh.2013.05.003]

92 **Nainan OV**, Xia G, Vaughan G, Margolis HS. Diagnosis of hepatitis a virus infection: a molecular approach. *Clin Microbiol Rev* 2006; **19**: 63-79 [PMID: 16418523 DOI: 10.1128/CMR.19.1.63-79.2006]

93 **Christenson JC**, Manaloor JJ. Hepatitis A, B, and C. *Pediatr Rev* 2016; **37**: 426-438 [PMID: 27694120 DOI: 10.1542/pir.2015-0075]

94 **Ji F**, Dang S, Cai Z, Xue H, Huang N, Liu L, Zhang S, Guo Y, Jia X, Wang Y, Li Z, Deng H. [Antiviral treatment and long-term clinical outcome of decompensated cirrhotic patients with hepatitis C virus infection]. *Zhonghua Gan Zang Bing Za Zhi* 2015; **23**: 647-652 [PMID: 26524356 DOI: 10.3760/cma.j.issn.1007-3418.2015.09.003]

95 **Wei L**, Lok AS. Impact of new hepatitis C treatments in different regions of the world. *Gastroenterology* 2014; **146**: 1145-50.e1-4 [PMID: 24662488 DOI: 10.1053/j.gastro.2014.03.008]

96 **Janssen HL**, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, Simon C, So TM, Gerken G, de Man RA, Niesters HG, Zondervan P, Hansen B, Schalm SW; HBV 99-01 Study Group; Rotterdam Foundation for Liver Research. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. *Lancet* 2005; **365**: 123-129 [PMID: 15639293 DOI: 10.1016/S0140-6736(05)17701-0]

97 **Heathcote EJ**, Marcellin P, Buti M, Gane E, De Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Gurel S, Snow-Lampart A, Borroto-Esoda K, Mondou E, Anderson J, Sorbel J, Rousseau F. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. *Gastroenterology* 2011; **140**: 132-143 [PMID: 20955704 DOI: 10.1053/j.gastro.2010.10.011]

98 **Due OT**, Thakkinstian A, Thavorncharoensap M, Sobhonslidsuk A, Wu O, Phuong NK, Chaikledkaew U. Cost-Utility Analysis of Direct-Acting Antivirals for Treatment of Chronic Hepatitis C Genotype 1 and 6 in Vietnam. *Value Health* 2020; **23**: 1180-1190 [PMID: 32940236 DOI: 10.1016/j.jval.2020.03.018]

**Footnotes**

**Conflict-of-interest statement:** None of the authors has any conflict of interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Corresponding Author's Membership in Professional Societies:** American Gastroenterological Association, No. 1104692.

**Peer-review started:** January 27, 2021

**First decision:** February 25, 2021

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Ireland

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): 0

Grade D (Fair): D, D

Grade E (Poor): 0

**P-Reviewer:** Masuzaki R **S-Editor:** Wang JL **L-Editor: P-Editor:**

**Table 1 Comparison of hepatotropic viruses hepatitis A-E**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Hepatitis** | **A** | **B** | **C** | **D** | **E** |
| Viral structure | Naked, ssRNA (Picornavirus) | Envelope, dsDNA (Hepadnavirus) | Envelope, ssRNA (Flavivirus) | Envelope, ssRNA (-ve) (Deltavirus) | Naked, ssRNA (Hepevirus) |
| Transmission | Faecal-oral | Parenteral, sexual | Parenteral, sexual | Parenteral, sexual | Faecal-oral |
| Incidence | 1.4 million | > 250 million[88] | > 80 million | About 12 million (prevalence)[89] | 20 million |
| Chronic infection | No | About 90% of infants infected; about 2%-6% adult infected | 70% (55%-85%) | < 5% of those infected with HBV, > 80% of superinfection)[90] | No (very rarely in immunosuppressed adults)[91] |
| Other disease associations | None | HCC, cirrhosis | HCC, cirrhosis | Cirrhosis, fulminant hepatitis | None (cirrhosis in chronic HEV infection) |
| Treatment | Supportive | Viral suppressive therapy (see criteria for commencement of treatment below) | Eradication therapy DAA (gold standard) | PEG-IFN (sparse data) | Supportive |

HBV: Hepatitis B virus; HEV: Hepatitis E virus; HCC: Hepatocellular carcinoma; DDA: Direct-acting antiviral.

**Table 2 Diagnosing hepatitis A-E**

|  |  |  |
| --- | --- | --- |
| **Hepatitis** | **Serological testing** | **Molecular testing (*via* PCR), quantitative** |
| A | Anti-HAV IgM (acute); Anti-HAV IgG (previous infection, vaccination); Note incubation period of 28 d[92] | HAV RNA |
| B | Anti-HBc (contact with HBV infection); HBsAg (current infection) appears 1-3 wk post exposure, duration > 24 wk denotes chronicity; Anti-HBS (vaccination, cleared HBV infection); HBeAg (high replication phase (> 10000 IU/mL); Anti-HBe (low replication phase (< 10000 IU/mL); Note incubation 90 d (ranges 45-160 d); Window period 1: first about 8 d of infection; Window period 2: clearance of HBsAg during this period Anti-HBc IgM is detectable[93] | HBV DNA |
| **C** | Anti-HCV: Note incubation 6-7 wk (ranges 2 wk to 6 mo)[93] | HCV RNA |
| D | Anti- HDV IgG | HDV RNA |
| E | Anti-HEV IgM and IgG and IgA | HEV RNA |

HBV: Hepatitis B virus; HCV: Hepatitis C virus; HDV: Hepatitis D virus; HEV: Hepatitis E virus; PCR: Polymerase chain reaction; HBsAg: Hepatitis B surface antigen.

**Table 3 European Association for the Study of the Liver 2017 clinical practice guidelines on the management of hepatitis B virus infection[12]**

|  |
| --- |
| **Clinical practice guidelines** |
| All patients with HBeAg-positive or -negative chronic hepatitis B, defined by HBV DNA (2000 IU/mL, ALT) upper limit of normal (ULN) and/or at least moderate liver necroinflammation or fibrosis, should be treated (Evidence level I, grade of recommendation 1) |
| Patients with compensated or decompensated cirrhosis need treatment, with any detectable HBV DNA level and regardless of ALT levels (Evidence level I, grade of recommendation 1) |
| Patients with HBV DNA (20000 IU/mL, and ALT) 2 × ULN should start treatment regardless of fibrosis degree (Evidence level II-2, grade of recommendation 1) |
| Patients with HBeAg-positive chronic HBV infection, defined by persistently normal ALT and high HBV DNA levels, may be treated if they are older than 30 years regardless of the severity of liver histological lesions (Evidence level III, grade of recommendation 2) |
| Patients with HBeAg-positive or HBeAg-negative chronic HBV infection and family history of HCC or cirrhosis and extra-hepatic manifestations can be treated even if typical treatment indications are not fulfilled (Evidence level III, grade of recommendation 2) |

HBV: Hepatitis B virus; HBeAg: Hepatitis B e-antigen; ALT: Alanine transaminase.

**Table 4 Comparing pegylated-interferon therapy to nucelos(t)ide analogues therapy**

|  |  |  |
| --- | --- | --- |
|  | **PEG-IFN** | **NA** |
| Route of administration | Subcutaneous | Oral |
| Length of treatment | 48 wk | Long-term in chronic HBV (stopping may be considered in some cases[13]); 8-16 wk in HCV |
| Contraindications | Many (*i.e.*, decompensated disease, comorbidities) | None (dose adjustment according to eGFR) |
| Tolerance | Inferior tolerability | Excellent tolerance |
| Side effects | Significant adverse events (psychiatric, neurologic, endocrinological) | Renal impairment (some DAA)[12] |
| SVR in HCV | 40%-75%[94,95] | > 90%[46] |
| Efficacy in chronic HBV | > 30% HBeAg loss; 3%-5% HBsAg loss[96] | > 11%-18% eAg loss (lower rate of HBeAg seroconversion); Very low HBsAg loss[97] |
| Cost | Expensive | Expensive when given long-term (*i.e.,* chronic HBV infection)[98] |
| Resistance | No | Yes |

PEG-IFN: Pegylated interferon; NA: Nucelos(t)ide analogues; HCV: Hepatitis C virus; HBeAg: Hepatitis B e-antigen; HBV: Hepatitis B virus; HBsAg: Hepatitis B surface antigen; DDA: Direct-acting antiviral.

**Table 5 First-line recommended direct-acting antiviral therapies for hepatitis C patients**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Genotype** | **1** | **2** | **3** | **4** | **5/6** |
| DAA schedule (non-cirrhotic) | Sofosbuvir/LedipasvirOr Glecaprevir/Pibrentasvir | Sofosbuvir/Velpatasvir | Sofosbuvir/Velpatasvir | Sofosbuvir/Ledipasvir | Sofosbuvir/Ledipasvir |
| Duration | 8-12 wk | 12 wk | 12 wk | 12 wk | 12 wk |
| DAA schedule (cirrhotic) | Sofosbuvir/Ledipasvir | Sofosbuvir/Velpatasvir | Glecaprevir/Pibrentasvir | Sofosbuvir/Ledipasvir | Sofosbuvir/Ledipasvir |
| Duration | 12 wk | 12 wk | 8-16 wk | 12 wk | 12 wk |

DDA: Direct-acting antiviral.